×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Handelsbanken Fonder AB Invests $101000 in Replimune Group, Inc. (NASDAQ:REPL)
Defense World
Read Handelsbanken Fonder AB Invests $101000 in Replimune Group, Inc. (NASDAQ:REPL) at Defense World.
1 day ago
Replimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash Runway
Yahoo Finance
Replimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash Runway · Net Loss: Reported a net loss of $51.1 million for the...
2 months ago
After Data Miss in Lead Cancer Indication, Replimune Maps Path for Oncolytic Virus
MedCity News
Cutaneous squamous cell carcinoma that does not respond to treatment with an immunotherapy called a checkpoint inhibitor has no FDA-approved...
5 months ago
Disc Medicine Taps Ex-Replimune Exec for CFO, Promotes New Operations Chief
MarketWatch
By Dean Seal Disc Medicine has hired the former chief financial officer of Replimune Group and promoted one of its C-suite members to chief...
2 months ago
Replimune shares halve as skin cancer drug fails phase 2
Fierce Biotech
Replimune's RP1 is an “active agent” according to CEO Philip Astley-Sparke, but it didn't achieve the primary endpoints of complete response...
5 months ago
RP1 Plus Cemiplimab Misses Response End Points in Locally Advanced or Metastatic CSCC
OncLive
The combination of RP1 and cemiplimab provided a numerical, but not statistically significant, improvement in response rates vs cemiplimab...
4 months ago
Replimune Group Announces Major Executive Team Overhaul - TipRanks.com
Tipranks
An announcement from Replimune Group Inc (REPL) is now available. Replimune Group, Inc. has announced a significant reshuffling of its...
1 month ago
REPL Stock Quote Price and Forecast
CNN
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of...
4 months ago
Petri Dish: NIH sends BioNTech notice of default; Intellia ends Regeneron deal - Boston Business Journal
The Business Journals
In today's Petri Dish: Why Replimune Group is shaking up its C-suite, how BioNTech is reacting to a notice of default from the NIH and more.
1 month ago
Replimune appoints new CEO ahead of drug application
Investing.com
WOBURN, Mass. - Replimune Group, Inc. (NASDAQ: NASDAQ:REPL), a biotechnology firm at the clinical stage, announced a reshuffle in its...
1 month ago